ArticleFrontiers in microbiology2020
A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistantAntimicrobial agents and chemotherapy · 2026Article
- Immunopathological outcomes are isolate dependent in chronic Mycobacterium avium complex pulmonary disease.Disease models & mechanisms · 2026Article
- Persistence of colistin-resistant Escherichia coli and the mcr-1 gene in the poultry chain, after the colistin ban.Veterinary research communications · 2025Article
- Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen againstAntimicrobial agents and chemotherapy · 2025Article
- Human mesenchymal stromal cells inhibitThorax · 2024Article
- Protein-energy restriction-induced lipid metabolism disruption causes stable-to-progressive disease shift in Mycobacterium avium-infected female mice.EBioMedicine · 2024Article
- Review
- Clofazimine as a substitute for rifampicin improves efficacy ofAntimicrobial agents and chemotherapy · 2024Article
- A Novel Inhibitor against the Biofilms of Non-Tuberculous Mycobacteria.Pathogens (Basel, Switzerland) · 2023Article
- Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection.Scientific reports · 2023Article
- Article
- Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review.Infectious diseases and therapy · 2023Review
- Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection againstVirulence · 2022Article
- Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection.Antimicrobial agents and chemotherapy · 2022Article
- In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.BMC microbiology · 2022Article
- Exacerbation ofVirulence · 2021Article
- Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy.Microbiology spectrum · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment outcomes using the standard regimen (a macrolide, ethambutol, and rifampicin) for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.